Edan Instruments

Edan Instruments Equity Ratio

The Equity Ratio of Edan Instruments (300206.SZ) as of Oct 27, 2026 is 82.94 %. In the previous year, Equity Ratio was 83.79 % — a change of -1.01% (lower).

Equity Ratio

82.94 %

YoY

-1.01%

Last updated:

Equity Ratio of Edan Instruments is 2025 82.94 % . Equity Ratio of Edan Instruments was 2024 83.79 % . It decreases by -1.01% lower compared to the previous year.

The Edan Instruments Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
86.41 CNY
Jan 1, 2019
86.23 CNY
Jan 1, 2020
80.16 CNY
Jan 1, 2021
84.61 CNY
Jan 1, 2022
82.89 CNY
Jan 1, 2023
88.78 CNY
Jan 1, 2024
83.79 CNY
Jan 1, 2025
82.94 CNY
The Edan Instruments Equity Ratio history
YEAREquity RatioYoY
82.94 %-1.01%
83.79 %-5.62%
88.78 %+7.10%
82.89 %-2.03%
84.61 %+5.55%
80.16 %-7.04%
86.23 %-0.20%
86.41 %-0.09%
86.48 %+5.53%
81.95 %+0.37%
81.65 %-4.76%
85.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Edan Instruments Stock analysis

What does Edan Instruments do? Edan Instruments, Inc. generates revenue through the design, manufacture, and sale of medical equipment, including maternity product series like doppler fetal heart beat monitors, ultrasonic doppler fetal heart beat monitors, fetal/maternal monitors, and maternity integrated diagnostic monitoring systems. The company also sells electrocardiograph series such as digital twelve-channel electrocardiographs, digital six-channel electrocardiographs, and electrocardiographic workstations, along with monitoring products like portable multi-variable monitors and central monitoring systems. Additionally, Edan offers spare parts and in vitro diagnostics products to support its equipment and medical services. The primary buyers of Edan's products are healthcare institutions, including hospitals and clinics, which purchase medical devices for diagnostic and monitoring purposes. These institutions rely on Edan's maternity, electrocardiograph, and monitoring systems to provide patient care. The company's in vitro diagnostics products are also sold to medical facilities for laboratory testing needs. Edan's product segments are defined by medical equipment categories: maternity, electrocardiograph, monitoring, and ultrasonic image systems. The spare parts and in vitro diagnostics businesses complement these segments by providing essential accessories and diagnostic tools. Revenue is derived from direct sales of these products to healthcare providers, with no mention of third-party distribution or additional services beyond the described offerings. Edan Instruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Edan Instruments stock

Equity Ratio of Edan Instruments is 82.94 % in 2025.

Equity Ratio of Edan Instruments changed from 83.79 % to 82.94 %, representing a -1.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Edan Instruments since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Edan Instruments with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Edan Instruments

All Key Metrics — Edan Instruments